Stockreport

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile Parallel Phase 2b trials, BROAD [Read more]